Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announces the hiring of two senior executives. Paul Hoskins, Senior Director of Clinical Operations and G. Michael Wall, PhD, Senior Director of Pharmaceutical Development joined the company this past month. Read More
Sound Pharmaceuticals, a leader in developing novel drug treatments for diseases of the inner ear, announced today that Jonathan Kil, MD, Co-Founder and Chief Executive Officer, has been invited to present at the 15th Annual Needham & Company Healthcare Conference on Wednesday, April 13th, 2016 at 11:20 a.m. EST in New York, NY. Read More
Sound Pharmaceuticals today announced the appointment of Paul Rickey as Chief Financial Officer (CFO). Paul Rickey, an experienced life sciences and technology industry executive, joined the company effective March 1, 2016. Paul will lead the company’s financial and administrative operations. Read More
Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately one percent of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which has significant side effects. Read More
(CNN) “Hey dude — can you turn your music down?”
If anyone says this to you while you’re wearing your earbuds, take note: You are probably endangering your hearing.
More than one billion teens and young adults are at risk of losing their hearing, according to WHO (that’s the World Health Organization, not the rock band).
It’s not just old folks who suffer hearing loss. Just by listening to music at what you probably think is a normal level, or hanging out in loud bars, nightclubs and music and sporting events, you can permanently damage your hearing.
Full Article here: